MannKind Corporation (MNKD)
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
MannKind: New Approvals Majorly Increase MannKind's Prospects
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Q2 Earnings Call Highlights
MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
MannKind NASDAQ: MNKD reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability.
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload.
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into children and adolescents.
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
